Skip to content

Determining the use of smart watches to detect irregular heart rhythms for people following a stroke

Evaluation of Huawei smartwear for detection of atrial fibrillation in a post-stroke population: the Huawei stroke study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN30693819
Enrollment
1000
Registered
2022-01-13
Start date
2022-03-14
Completion date
Unknown
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Detection of atrial fibrillation in patients who have experienced a stroke Circulatory System

Interventions

We are planning this study for people who have recently had a confirmed ischaemic stroke. We will ask people to take part in the study before they leave hospital following their stroke. We will collec

Sponsors

University of Liverpool
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 199 Years

Inclusion criteria

Inclusion criteria: 1. >=18 years old 2. Current in-patient at the time of baseline data collection for recent ischaemic stroke; confirmed by stroke physician and/or imaging (computerized tomography (CT) or magnetic resonance imaging (MRI))

Exclusion criteria

Exclusion criteria: 1. Inability to provide informed consent 2. Receiving palliative or end-of-life care

Design outcomes

Primary

MeasureTime frame
Detection of atrial fibrillation by the Huawei smart band measured continuously up to week 4

Secondary

MeasureTime frame
Patient outcomes: 1. Performance in activities of daily living measured using the Barthel Index at baseline, 6 months and 12 months. 2. General health measured using the Patient Health Questionnaire (PHQ)-9 at baseline, 6 months and 12 months. 3. Anxiety measured using the General Anxiety Disorder (GAD)-7 at baseline, 6 months and 12 months. 4. Obstructive Sleep Apnea measured using the STOP BANG questionnaire at baseline, 6 months and 12 months. 5. Health related quality of life measured using the EQ-5D-5L at baseline, 6 months and 12 months. 6. Modified European Heart Rhythm Association (mEHRA) symptom score measured at baseline, 6 months and 12 months. 7. Treatment burden questionnaire measured at baseline, 6 months and 12 months. 8. Montreal Cognitive Assessment (MoCA) measured at baseline and 12 months. 9. Participant ‘intervention acceptability’ survey measured at one-month. 10. Participant interviews, conducted with a sub-sample of patients to explore intervention acceptability at one-month. Outcomes measured in staff involved in training participants to use the smart bands: 11. Staff interviews to explore challenges in delivery of the training to participants to use the smart bands, time taken (to deliver the intervention and ongoing support with the system provided to the patient), unexpected benefits and/or consequences, and recommendations for improvement at six months. 12. Staff ‘intervention acceptability’ survey measured at baseline.

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 12, 2026